Phillip Md Et Al Frost Buys 50,000 Shares of OPKO Health, Inc. (NASDAQ:OPK) Stock

OPKO Health, Inc. (NASDAQ:OPKGet Rating) CEO Phillip Md Et Al Frost acquired 50,000 shares of the company’s stock in a transaction dated Wednesday, May 25th. The stock was acquired at an average price of $2.98 per share, for a total transaction of $149,000.00. Following the completion of the purchase, the chief executive officer now directly owns 196,006,694 shares of the company’s stock, valued at approximately $584,099,948.12. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Wednesday, May 18th, Phillip Md Et Al Frost acquired 50,000 shares of OPKO Health stock. The stock was acquired at an average price of $2.88 per share, for a total transaction of $144,000.00.
  • On Monday, May 16th, Phillip Md Et Al Frost acquired 150,000 shares of OPKO Health stock. The stock was acquired at an average price of $2.98 per share, for a total transaction of $447,000.00.
  • On Friday, May 13th, Phillip Md Et Al Frost acquired 200,000 shares of OPKO Health stock. The stock was acquired at an average price of $3.00 per share, for a total transaction of $600,000.00.
  • On Tuesday, May 10th, Phillip Md Et Al Frost acquired 400,000 shares of OPKO Health stock. The stock was acquired at an average price of $2.78 per share, for a total transaction of $1,112,000.00.
  • On Monday, March 14th, Phillip Md Et Al Frost bought 35,000 shares of OPKO Health stock. The shares were purchased at an average cost of $3.04 per share, for a total transaction of $106,400.00.
  • On Friday, March 11th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were purchased at an average cost of $3.13 per share, for a total transaction of $313,000.00.
  • On Monday, February 28th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were purchased at an average cost of $3.11 per share, for a total transaction of $311,000.00.
  • On Friday, February 25th, Phillip Md Et Al Frost bought 750,000 shares of OPKO Health stock. The shares were purchased at an average cost of $3.09 per share, for a total transaction of $2,317,500.00.

Shares of OPK opened at $3.02 on Thursday. The company has a market capitalization of $2.06 billion, a P/E ratio of -16.78 and a beta of 1.88. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.44 and a quick ratio of 2.12. OPKO Health, Inc. has a one year low of $2.43 and a one year high of $5.25. The business’s 50 day simple moving average is $3.18 and its 200-day simple moving average is $3.61.

OPKO Health (NASDAQ:OPKGet Rating) last announced its earnings results on Monday, May 9th. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02). The business had revenue of $329.20 million during the quarter, compared to analyst estimates of $331.45 million. OPKO Health had a negative return on equity of 6.86% and a negative net margin of 7.49%. The firm’s revenue was down 39.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.05 earnings per share. On average, sell-side analysts anticipate that OPKO Health, Inc. will post -0.21 EPS for the current fiscal year.

OPK has been the topic of a number of recent research reports. StockNews.com began coverage on OPKO Health in a research report on Thursday, March 31st. They set a “sell” rating on the stock. Piper Sandler decreased their price objective on OPKO Health from $6.00 to $5.00 in a report on Tuesday, May 10th. Finally, TheStreet downgraded OPKO Health from a “c” rating to a “d+” rating in a report on Friday, February 25th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $6.00.

Hedge funds have recently bought and sold shares of the stock. Cornerstone Advisory LLC bought a new position in OPKO Health in the 4th quarter worth approximately $29,000. Russell Investments Group Ltd. bought a new stake in shares of OPKO Health during the 4th quarter valued at $50,000. American Century Companies Inc. bought a new stake in shares of OPKO Health during the 4th quarter valued at $51,000. Humankind Investments LLC bought a new stake in shares of OPKO Health during the 1st quarter valued at $37,000. Finally, Guggenheim Capital LLC bought a new stake in shares of OPKO Health during the 1st quarter valued at $38,000. Hedge funds and other institutional investors own 27.83% of the company’s stock.

About OPKO Health (Get Rating)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.

Further Reading

Insider Buying and Selling by Quarter for OPKO Health (NASDAQ:OPK)

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.